Checkpoint Therapeutics, INC

Checkpoint Therapeutics, Inc. has finalized its merger with Sun Pharmaceutical Industries, Inc., becoming a wholly-owned subsidiary and delisting from Nasdaq, with shareholders receiving $4.10 cash per share plus a contingent value right.

Checkpoint Therapeutics, Inc. stockholders have overwhelmingly approved the Agreement and Plan of Merger with Sun Pharmaceutical Industries, Inc., moving the company closer to becoming a wholly-owned subsidiary of Sun Pharma.

Checkpoint Therapeutics and Sun Pharma's merger progresses as the Hart-Scott-Rodino waiting period expires, with the deal expected to close around May 30, 2025, pending stockholder approval and other customary conditions.

Checkpoint Therapeutics reported its Q1 2025 financial results, highlighted by FDA approval of UNLOXCYT and an upcoming stockholder vote on a merger with Sun Pharmaceutical Industries.

Checkpoint Therapeutics and Sun Pharmaceutical Industries amend their merger agreement, modifying the definition of 'Company Required Vote' to include both a majority of unaffiliated stockholders and a majority of outstanding common stock.

Checkpoint Therapeutics reports its full-year 2024 financial results, highlighted by the FDA approval of UNLOXCYT and a pending merger agreement with Sun Pharmaceutical Industries.

Checkpoint Therapeutics reports its Q1 2025 financial results and provides an update on its pending merger with Sun Pharmaceutical Industries.

Checkpoint Therapeutics reported its Q3 2024 financial results, highlighting ongoing losses and substantial doubt about its ability to continue as a going concern.

Checkpoint Therapeutics announced its Q2 2024 financial results and the FDA's acceptance of its resubmitted Biologics License Application (BLA) for cosibelimab.

Checkpoint Therapeutics' first quarter results reflect ongoing losses and reliance on future financing to continue development of its cancer treatment candidates.

Checkpoint Therapeutics' 2024 10-K filing highlights the FDA approval of UNLOXCYT and a pending merger with Sun Pharmaceutical Industries, while also detailing the company's financial losses and future strategies.

Checkpoint Therapeutics' 10-K filing details its capital structure, ongoing clinical programs, and financial position, highlighting both opportunities and challenges.

Fortress Biotech, a significant shareholder and director, has fully divested its holdings in Checkpoint Therapeutics following the company's acquisition by Sun Pharmaceutical Industries for $4.10 per share plus a contingent value right.

Checkpoint Therapeutics, Inc. Director and 10% owner Michael S. Weiss has disposed of all his common stock holdings, totaling 187,007 shares, as part of a merger agreement for $4.10 cash per share plus a contingent value right.

Checkpoint Therapeutics Director Barry M. Salzman has disposed of all his common stock holdings, totaling 147,007 shares, in connection with the previously announced merger agreement, receiving $4.10 per share in cash plus a contingent value right.

Checkpoint Therapeutics Director Lindsay A. Rosenwald MD disposed of 207,007 shares of common stock in connection with a merger agreement, receiving $4.10 per share in cash and one contingent value right per share.

Checkpoint Therapeutics' CEO, James F. Oliviero III, has disposed of 3,759,929 shares of common stock in connection with a previously announced merger agreement, receiving $4.10 cash per share plus a contingent value right.

A director of Checkpoint Therapeutics, Neil Herskowitz, has disposed of all his shares in the company as part of a previously announced merger agreement, receiving cash and contingent value rights.

Checkpoint Therapeutics is holding a special meeting on May 28, 2025, for stockholders to vote on the proposed merger with Sun Pharmaceutical Industries, Inc.

Checkpoint Therapeutics and Sun Pharmaceutical Industries amend their merger agreement, modifying the definition of 'Company Required Vote' to include both a majority of unaffiliated stockholders and a majority of outstanding common stock.

Checkpoint Therapeutics announces a definitive agreement to be acquired by Sun Pharmaceutical Industries, Inc., pending stockholder approval and regulatory clearances.

Sun Pharmaceutical Industries will acquire Checkpoint Therapeutics for an upfront cash payment of $4.10 per share plus a contingent value right of up to $0.70 per share, potentially reaching a total transaction value of $416 million.

Checkpoint Therapeutics is holding its annual meeting on May 13, 2024, seeking stockholder approval on several key proposals, including increasing authorized shares and amending the 2015 Incentive Plan.

Checkpoint Therapeutics is asking stockholders to approve an increase in authorized shares and an amendment to its incentive plan at the upcoming annual meeting.

Beryl Capital Management and affiliates report 0% beneficial ownership in Checkpoint Therapeutics, Inc., indicating a full divestment.